

医渡科技 3 月通讯 | 2023 年

Yidu Tech Events in March 2023

集团亮点

Business Update

医渡科技与光大海外联合组织调研座谈会，多家机构走进温医大眼视光医院

Yidu Tech and Everbright Securities Overseas organized a research seminar, and multiple institutions visited the Eye Hospital of Wenzhou Medical University

由医渡科技与光大海外联合组织的“数字中国战略和数字经济发展时代下，头部研究型医院高质量发展调研座谈会”在温州医科大学附属眼视光医院成功举办。在光大海外的带领下，近 20 位头部投资机构走进温医大眼视光医院和中国眼谷，通过现场交流和参观，进一步了解中国头部研究型医院利用创新技术推动高质量发展的路径和成果，以及医渡科技数字化、智能化平台及解决方案在助力医院临床研究、诊疗和管理中的作用和意义。

The seminar named “High-Quality Development of Leading Research Hospitals in the Era of Digital China Strategy and Digital Economy Development” was successfully held by Yidu Tech and Everbright Securities Overseas. Nearly 20 leading investment institutions visited Eye Hospital of Wenzhou Medical University and China Eye Valley for on-site exchanges. Therefore, these institutions can further understand the achievements of China’s top research hospitals in promoting high-quality development through innovative technologies, and significance of Yidu Tech’s digitalization strategy, intelligent platform and solutions in supporting clinical research, diagnosis and treatment, as well as hospital management.



医渡科技旗下医渡云承办的第二期 CDO 班成功举办

The second Chief Data Officer (CDO) class was successfully held by YiduCloud, the subsidiary of Yidu Tech

由《中国卫生信息管理杂志》、华中科技大学同济医学院医药卫生管理学院主办，医渡科技旗下医渡云承办的首届全国医疗健康首席数据官（CDO）系列研讨活动（第二期）在海口成功举办。多名数据科学、卫生信息管理领域的专家受邀参会，并围绕“从多维数据应用到卓越价值创造”主题展开分享，来自全国公立医疗机构、公共卫生机构的信息业务骨干参加，多维度、多层次地探讨了医疗健康数据的深度利用及价值创造。

The first National Healthcare Chief Data Officer (CDO) Series Seminar (Phase II), co-hosted by Chinese journal of health information & management and Tongji Medical College of Huazhong University of Science & Technology School of Medicine and Health Management, was successfully held in Haikou. Experts in the field of data science and health information management were invited to attend the event, and shared their insights on the theme of “From Multi-dimensional Data Application to Excellent Value Creation”. Information business cadres from public medical institutions and public health institutions across the country participated, discussing the in-depth utilization of healthcare data and value creation in a multi-dimensional manner.



医渡科技戴鲁燕博士受邀出席第二届创新药商业化高峰论坛

Dr. Dai Luyan from Yidu Tech was invited to attend The Second Innovative Medicine Commercialization Summit

天风证券第二届创新药商业化高峰论坛在上海举行，会议邀请多位政策、产业、临床领域的专家，共同探讨挖掘创新药行业发展的新趋势、新起点。医渡科技旗下开心生活科技（HLT）战略与创新副总裁戴鲁燕博士受邀做报告，主题为“真实世界研究助力创新药企数字化转型”。戴博士认为，医学循证是药企寻找构建差异化及竞争优势的重要基石，医学证据的产生成为新商业化模式的关键。

The Second Innovative Medicine Commercialization Summit was held in Shanghai by Tianfeng Securities. The conference invited experts from the policy, industry and clinical fields to discuss new starting points for the development of the innovative medicine industry. Dr. Dai Luyan, Vice President of Strategy and Innovation of Happy Life Tech (HLT), a subsidiary of Yidu Tech, was invited to give a presentation on the topic of “Real-World Research Supporting the Digital Transformation of Innovative Pharmaceutical Companies”. According to Dr. Dai, the evidence-based medicine is cornerstone for pharmaceutical companies to build differentiation and competitive advantages, and the generation of medical evidence becomes the key factor in new commercialization models.



沙特阿拉伯人社部前副部长率科创代表团到访医渡科技

Saudi Arabia's former Deputy Minister of Human Resources and Social Affairs led a delegation of science innovation representatives to visit Yidu Tech

沙特阿拉伯人力资源与社会部前副部长穆罕默德·贾塞尔（H.E. Mohammed Bin Nasser Bin Ali Al-Jasser）阁下率领科创代表团到访医渡科技集团，启迪控股副总裁、启迪之星执行总裁、启迪技转总裁韩威先生等人随同到访。医渡科技董事长兼创始人宫如璟女士携公司管理团队热情接待了贵宾，并围绕推进沙特与医渡科技多元化、多形式的合作展开座谈。

H.E. Mohammed Bin Nasser Bin Ali Al-Jasser, the Assistant to the Minister of Labor and Social Development of Saudi Arabia, led a delegation of science innovation representatives to visit Yidu Tech, accompanied by Mr. Han Wei, Vice President of Tus-Holdings Co., Ltd., Executive General Manager of TusPark Business Incubator Co., Ltd. and President of TusPark International Technology Transfer Co., Ltd. Ms. Gong Rujing, Chairlady of the Board, and Founder of Yidu Tech, together with the management team of the company, warmly welcomed the

distinguished guests and engaged in the discussion on promoting multi-dimensional cooperation between Saudi Arabia and Yidu Tech.



业务进展

Business Porgress

医渡云助力《套细胞淋巴瘤标准数据集》发布，MCL 科研成果转化再提速
YiduCloud helps to release the “Standard Data Set for Mantle Cell Lymphoma” and speed up the transformation of MCL research results

在第九届苏州淋巴瘤会议上，由国家血液系统疾病临床医学研究中心、中华医学会血液学分会和苏州大学附属第一医院血液科共同组织编写，医渡科技旗下医渡云提供技术支持的《套细胞淋巴瘤标准数据集》正式发布。该数据集为后续研究者开展套细胞淋巴瘤（MCL）真实世界研究奠定了扎实的数据基础。

At the 9th Suzhou Lymphoma Conference, the *Standard Dataset for Mantle Cell Lymphoma* was officially released. This dataset was compiled by National Clinical Research Centre for Blood Diseases, the Hematology Branch of the Chinese Medical Association, and the Department of Hematology of the First Affiliated Hospital of Suzhou University, with technical support from YiduCloud, a subsidiary of Yidu Tech. This dataset has laid a solid data foundation for subsequent researchers to conduct real-world studies on Mantle Cell Lymphoma (MCL).



国家药监局海南真实世界数据研究与评价重点实验室携手 HLT 在国际期刊发表学术论文

The National Medical Products Administration Hainan Real World Data Research and Evaluation Key Laboratory in collaboration with Happy Life Tech published an academic essay in the international journal

国家药监局海南真实世界数据研究与评价重点实验室与医渡科技旗下开心生活科技合作撰写的论文《Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in “Boao Lecheng Pilot Zone”》在国际期刊《Cost Effectiveness and Resource Allocation》上发表，HLT 李佳禾为论文第一作者，重点实验室主任孙鑫教授为通讯作者。

The paper *Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in “Boao Lecheng Pilot Zone*, co-written by the Hainan Key Laboratory of Real World Data Research and Evaluation of the National Medical Products Administration and Happy Life Tech, a subsidiary of Yidu Tech, was published in the international

journal *Cost Effectiveness and Resource Allocation*, with HLT's Li Jiahe as the first author and Professor Sun Xin, Director of the Key Laboratory, as corresponding author.

Li et al.
Cost Effectiveness and Resource Allocation (2023) 21:7
<https://doi.org/10.1186/s12962-022-00412-w>

Cost Effectiveness and
Resource Allocation

REVIEW

Open Access

Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in “Boao Lecheng Pilot Zone”



Jiahe Li¹, Lichang Liu², Haijun Cao², Mei Yang³ and Xin Sun^{4*}

医渡云中标华中某头部研究型医院数据治理一体化中台项目

YiduCloud won the bid for data governance integration of the middle platform project from a top-tier research hospital in central China

该项目充分体现公司医疗大数据治理能力，公司将运用新一代信息技术，结合先进的数据中台理念，实现全院数据统一采集、统一治理、统一管理、统一开放，以信息化手段帮助医院提升数据治理和管理水平，并通过多项智慧化应用赋能医教研管，进一步助力医院高质量发展。

The project fully reflects the company's capabilities in healthcare big data governance. The company will use a new generation of information technology, combined with advanced data middle platform concept, to achieve unified data collection, governance, management, and opening access of hospital data, as well as improving their data governance and management capabilities by using information technology. Besides, hospitals can empower medical education, research and management through intelligent applications, further assisting the hospital's high-quality development.

医渡云中标华中某头部研究型医院全流程结算系统之多中心临床研究支撑平台建设项目

YiduCloud won the bid for the construction project of a multi-center clinical research support platform for the full process settlement system from a leading research hospital in Central China

医渡云将助力医院提升整体医学科研水平，建成国际水平的专病领域大数据库，赋能医院及相关医疗机构临床医学研究；帮助医院沉淀诊疗规范、构建专病数据标准，赋能各中心科研的长期发展，同时支撑多中心协同研究，助力提升研究效率。

YiduCloud will help the hospital improve its overall medical research level, building an internationally advanced big data bank in the field of specialized diseases, empowering the hospital and related medical institutions in clinical medical research; as well as assisting the hospital in establishing diagnostic and treatment norms, constructing specialized disease data standards, empowering the long-term development of research in each center, while supporting multi-center collaborative research to enhance research efficiency.

医渡科技旗下公司中标纳秒脉冲肿瘤消融系统用于胰腺癌注册临床研究（III期）项目

A subsidiary of Yidu Tech won the bid for Phase III research project in Nanosecond pulse tumor ablation system used for registered clinical study on pancreatic cancer

医渡科技旗下公司中标某全球领先的专注于脉冲电场高端医疗器械的高新技术企业临床研究项目，为其“纳秒脉冲肿瘤消融系统用于胰腺癌注册临床研究（III期）项目”提供临床研究服务及试验软件，包括现场管理组织（SMO）服务、电子数据采集系统（EDC）、中央随机化系统（IWRS）等。

A subsidiary of Yidu Tech was awarded the clinical research project by a leading global high-tech company specializing in pulsed electric field high-end medical devices, providing clinical research services and trial software for its "Nanosecond Pulsed Tumor Ablation System for Pancreatic Cancer Registration Clinical Study

(Phase III) Project", including on-site management organization (SMO) services, electronic data collection system (EDC), central randomization system (IWRS) etc.

HLT 中标某跨国药企的 IgA 肾病和狼疮性肾炎项目

HLT won the bid for IgA nephropathy and lupus nephritis project from a multinational pharmaceutical company

医渡科技旗下开心生活科技（HLT）中标某跨国药企的 IgA 肾病和狼疮性肾炎项目，为其提供人群 Phase1 阶段发表及 Phase2 可行性分析。这是继 2022 年以来，HLT 与该药企的第二次合作，标志着 HLT 与其长期合作关系的建立。IgA 肾病和狼疮性肾炎是严重威胁人类健康和生活质量的疾病，部分患者会进展为终末期肾病（ESRD），给患者带来极大的身心负担，该药企作为罕见病领域的领头企业之一，有着强大的研发能力，致力于将创新疗法带给更多患者。

Happy Life Tech (HLT) has won a bid for IgA nephropathy and lupus nephritis project from a multinational pharmaceutical company. HLT will provide Phase 1 population publication and Phase 2 feasibility analysis, marking the establishment of long-term partnership, and second collaboration between HLT and this pharmaceutical company since 2022. IgA nephropathy and lupus nephritis are serious diseases that threaten human health and quality of life. Some patients may develop to end-stage renal disease (ESRD), which brings great physical and mental burden to patients. As one of the leading enterprises in the rare disease field, the pharmaceutical company has strong research and development capabilities and is committed to bringing innovative therapies to more patients.

集团荣誉

Group Awards

金 i 奖 | 医渡科技获评“2022 中国人工智能产业年度企业”

Golden i Award | Yidu Tech won the award of “2022 China Artificial Intelligence Industry Annual Enterprise”



由中国科学院旗下权威媒体《互联网周刊》、中国社会科学院信息化研究中心、eNet 研究院、德本咨询联合主办的“2023(第八届)思维实验室论坛”成功举办。经过层层评选，医渡科技凭借人工智能技术实力和在医疗领域的创新应用能力，斩获“2022 中国人工智能产业年度企业”金 i 奖。

The 2023 (8th) Think Lab Forum, co-hosted by authoritative media “Internet Weekly” under the Chinese Academy of Sciences, the Informatization Technology Research Center of the Chinese Academy of Social Sciences, eNet Research Institute, and Deben Consulting, was successfully held. After layers of selection, Yidu Tech won the Golden i Award for “2022 China Artificial Intelligence Industry Annual Enterprise” by virtue of its strong artificial intelligence technology capabilities and innovative application abilities in the healthcare industry.



医渡科技上海办荣获“生命健康行业翘楚奖”和“超凡业绩奖”

Yidu Tech Shanghai Office Received “Outstanding Awards in Life and Health Industry” and “Excellent Performance Award”

“星河灿烂 集智追光”2023 虹梅领军企业年度颁奖典礼在上海举行。会上，医渡科技上海办荣获“生命健康行业翘楚奖”和“超凡业绩奖”，表明公司在生命健康领域有着卓越的影响力和硬核实力。

The “Star River Brilliant, Gathering Wisdom and Chasing Light” 2023 Hongmei Leading Enterprise Awards Ceremony was held in Shanghai. At the event, Yidu Tech’s Shanghai office was awarded the “Outstanding Awards in Life and Health Industry” and “Excellent Performance Award”, which demonstrating the company’s outstanding influence and strong capabilities in the healthcare industry.

行业洞察

Industry Insight

两会利好信号密集释放，提振医疗智能市场信心

The positive signals were released intensively from the Two Sessions, which has boosted confidence in the healthcare intelligence market

今年政府工作报告提出，大力发展数字经济，“科技创新”一词更是出现了 7 次，“以科技自立自强，守护人民生命健康”成为两会代表委员热议的话题，如“建议加大医疗人工智能企业的支持力度”、“建议用人工智能技术改造医药传统产业”等提案议案内容。此外，《党和国家机构改革方案》指出重新组建科学技术部、组建国家数据局，也体现了对科技创新和数字经济建设的重视。两会利好信号频出，为医疗智能行业按下发展加速键。

This year’s government work report proposed to vigorously develop the digital economy, the word “scientific and technological innovation” repeated seven times, “self-sustaining and self-improving with science and technology, guarding people’s life and health” has become a hot topic of discussion between delegates and members of the Two Sessions, such as “it is recommended to increase the support of healthcare artificial intelligence enterprises”, “it is recommended to use artificial intelligence technology to transform the traditional industry of medicine” and other proposals and motions. In addition, the *Party and National*

Institutional Reform Programme points out the re-establishment of the Ministry of Science and Technology and the formation of the National Data Bureau, which also reflects the importance attached to science and technology innovation and the construction of a digital economy. The Two Sessions are full of favorable signals, which press the accelerator button for the development of the healthcare intelligence industry.

中办国办印发《关于进一步完善医疗卫生服务体系的意见》

The General Office of the Communist Party of China and the General Office of the State Council have issued *Opinions on Further Improving the Healthcare Service System*

中共中央办公厅、国务院办公厅印发《关于进一步完善医疗卫生服务体系的意见》，提出发挥信息技术支撑作用，加快推进互联网、区块链、物联网、人工智能、云计算、大数据等在医疗卫生领域中的应用，加强健康医疗大数据共享交换与保障体系建设等，对于推动医疗智能行业发展、推动健康中国建设具有重要意义。

The General Office of the Communist Party of China and the General Office of the State Council have issued the *Opinions on Further Improving the Healthcare Service System*, which proposes to leverage information technology to accelerate the application of the Internet, blockchain, the Internet of Things, artificial intelligence, cloud computing, big data, and other technologies in the healthcare industry, strengthen the construction of a system for sharing and guaranteeing healthcare big data. This is of great significance in promoting the development of the healthcare intelligence industry and the construction of the Healthy China.